Belantamab Mafodotin
Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients With Relapsed Multiple Myeloma
What will happen during the trial?
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy.
Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
The purpose of this research is to gather information on the safety and effectiveness of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone for patients with a history of two or more prior lines of myeloma therapy. This combination is not FDA-approved, although carfilzomib and pomalidomide, are separately FDA-approved agents in combination with dexamethasone.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 55 patients (estimated)
- Sponsors
- University of Chicago
- Collaborators
- GlaxoSmithKline, Amgen
- Tags
- Antibody Drug Conjugate (ADC), B-Cell Maturation Antigen (BCMA), Quadruplet Therapy
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1459
- NCT Identifier
- NCT05789303
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.